Lyra Therapeutics (LYRA) Non-Current Assets (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Non-Current Assets of $19.8 million in Q4 2025, down 4.13% on a QoQ basis from $20.7 million in Q3 2025, and down 14.94% YoY from $23.3 million in Q4 2024.
Lyra Therapeutics (LYRA) Non-Current Assets (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Non-Current Assets for 7 consecutive years, with $19.8 million the latest figure, recorded in Q4 2025.
- Non-Current Assets for Q4 2025 came in at $19.8 million, down 14.94% year-over-year; the trailing twelve-month figure through Dec 2025 was $84.4 million (down 32.37% YoY), and the FY2025 annual result was $19.8 million, down 14.94% from the prior year.
- Non-Current Assets for Q4 2025 stood at $19.8 million, down from $20.7 million in the prior quarter.
- The five-year high for Non-Current Assets was $52.1 million in Q1 2024, with the low at $5.6 million in Q1 2021.
- A 5-year average of $16.8 million and a median of $12.4 million in 2022 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets jumped 474.31% in 2024 and tumbled 56.97% in 2025, its largest moves.
- Lyra Therapeutics' Non-Current Assets stood at $6.9 million in 2021, then jumped by 31.52% to $9.1 million in 2022, then soared by 313.38% to $37.8 million in 2023, then plunged by 38.27% to $23.3 million in 2024, then decreased by 14.94% to $19.8 million in 2025.
- The last three Non-Current Assets figures came in at $19.8 million (Q4 2025), $20.7 million (Q3 2025), and $21.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | 19.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 19.84 Mn |
| Sep 30, 2025 | 20.69 Mn |
| Jun 30, 2025 | 21.51 Mn |
| Mar 31, 2025 | 22.41 Mn |
| Dec 31, 2024 | 23.32 Mn |
| Sep 30, 2024 | 24.31 Mn |
| Jun 30, 2024 | 25.15 Mn |
| Mar 31, 2024 | 52.08 Mn |
| Dec 31, 2023 | 37.78 Mn |
| Sep 30, 2023 | 15.66 Mn |
| Jun 30, 2023 | 7.42 Mn |
| Mar 31, 2023 | 9.07 Mn |
| Dec 31, 2022 | 9.14 Mn |
| Sep 30, 2022 | 7.23 Mn |
| Jun 30, 2022 | 7.65 Mn |
| Mar 31, 2022 | 6.79 Mn |
| Dec 31, 2021 | 6.95 Mn |
| Sep 30, 2021 | 6.88 Mn |
| Jun 30, 2021 | 6.26 Mn |
| Mar 31, 2021 | 5.57 Mn |